The study was conducted at the University of Innsbruck, Germany. The study was carried out in two stages. The first stage was an interventional study in which the subjects were randomly assigned to receive either orlistat (120 mg/kg/day) or a placebo (100 mg/kg/day). The second stage was a double-blind, controlled trial that was carried out in three groups: The subjects in the placebo group were randomly assigned to receive either orlistat or a placebo. The subjects in the orlistat group were randomly assigned to receive either orlistat or a placebo. The dose of each drug was taken at bedtime with a light meal for 4 days. The dose of each drug was also taken at bedtime with a light meal for 6 days. The subjects received a standard diet consisting of 12, 12.5, 13, 13.5, or 16.5 g of fat, with a total of three meals per day. The study was performed in the autumn of 2015. The subjects in the placebo group were randomly assigned to receive either orlistat (30 mg/kg/day) or a placebo. Subjects were assessed using the World Health Organization Body Weight (WHOB) questionnaire, the World Health Organization (WHO) Body Fat Index (BFI) questionnaire, the International Index of Excessive Obesity (IIEF), and a scale (height) questionnaire. The study was conducted in three different groups: The subjects in the placebo group were randomly assigned to receive either orlistat (30 mg/kg/day) or a placebo. The subjects in the orlistat group were randomly assigned to receive either orlistat (30 mg/kg/day) or a placebo. Subjects were assessed using the WHOB questionnaire, the World Health Organization (WHO) Body Fat Index (BFI) questionnaire, the WHO Body Weight (WOB), and the International Index of Excessive Obesity (IIEF). In order to assess body composition and the WHOB questionnaire, the subjects in the placebo group were assessed using a modified International Index of Excessive Obesity (IIEF). In the orlistat group, a questionnaire was completed at the same time. The subjects in the placebo group received a standard diet consisting of 12, 12.5, 13, 13.5, or 16.5 g of fat, with a total of three meals per day. After the subjects were assessed, the subjects were asked to take an additional blood sample for testing at the same time. The blood samples were collected in EDTA tubes, and they were centrifuged at 10,000 rpm for 10 min. The supernatant was used in the test and the results were analyzed using the World Health Organization Body Weight (WHOB) questionnaire. The International Index of Excessive Obesity (IIEF) was also completed. The results of the study were analyzed using the WHO Body Fat Index (WHOB), the WHO Body Weight (WOB), and the International Index of Excessive Obesity (IIEF). The results of the study were analyzed using the WHO body fat index (IIEF) and the WHO body weight (WOB).
SubjectsSubjects were recruited in the autumn of 2015. They were between 18.0 and 82.7 years old. They were randomly assigned to either orlistat (60 mg/kg/day) or a placebo. The study was performed in three different groups: The subjects in the placebo group were randomly assigned to receive either orlistat (30 mg/kg/day) or a placebo. The subjects received a standard diet consisting of 12, 12.5, 13, or 13.5 g of fat, with a total of three meals per day.
Orlistat is a weight-loss medication that is approved for use in people who have a BMI of 30 or more. It works by decreasing the amount of fat you absorb from food and from body waste products. It is sold under the brand names Alli, Xenical, and AlliXen.
Orlistat comes in three different strengths, 120mg, 120mg, and 180mg. The 120mg strength is used for people who have a BMI of 30 or more. The 120mg strength is also available in a generic version called Xenical.
The 120mg strength of Orlistat comes in 120mg capsules. A 120mg capsule is usually taken once a day with food. A 120mg capsule is taken twice a day with food. The 120mg capsule should be taken with a full glass of water, but should be taken with a full glass of water with a meal. Orlistat is typically taken 1-3 times a day.
Orlistat is also sold under the brand names Alli and Xenical. Xenical is a generic version of Alli. The generic version of Alli is called AlliXEN.
Orlistat works by decreasing the amount of fat you absorb from food. It also reduces the amount of fat you absorb from the body. Orlistat is sold under the brand names Alli, Alli, and Xenical.
Orlistat is also available in a generic version called Xenical.
Orlistat is used to help people lose weight. It is a weight-loss drug, which means that you can lose weight using drugs like Xenical.
Orlistat is a prescription medication. It should not be used to treat obesity, especially if you have a BMI of 30 or more. It is also not approved for use in children and adolescents under the age of 18.
Orlistat can be taken with or without food. However, it should be taken at least 1 hour before or 2 hours after food. It is also not recommended to take orlistat more than once a day.
Orlistat is available in capsule form. Capsules are made of a drug called orlistat. They contain the active ingredient orlistat.
Orlistat works by helping to block the absorption of fat in your body. It works by blocking the absorption of fat in your stomach and intestines. It also helps to reduce the amount of fat you absorb from food and from body waste products.
Orlistat is a weight-loss drug. It is a medication that helps to decrease the amount of fat you absorb from food and from body waste products. It also is not approved for use in children and adolescents under the age of 18.Xenical is a prescription medication.
Orlistat is a medication.Orlistat is a medication that is used to help people lose weight. It works by decreasing the amount of fat you absorb from food. It also helps to reduce the amount of fat you absorb from body waste products. Orlistat is sold under the brand names Alli and Xenical. The generic version of Alli is called XenicalXEN.
Details
Alli Weight Loss Aid comes in a form of 60 mg orlistat capsules and is FDA approved for over-the-counter use. It is designed to aid in weight loss, working in conjunction with a reduced-calorie, low-fat diet by boosting weight loss efforts. Each refill pack provides up to a 56-day supply, containing 170 capsules and includes a'read me first' brochure with essential information for users. Unlike the starter pack, this refill does not come with a convenient carrying case or additional materials. Glaxosmithkline,
Show more
Ingredients
Active Ingredient (in each sealed capsule): Orlistat (60 mg). Inactive Ingredients: FD& C Blue 2,Edible Ink,Gelatin,Iron Oxide,Microcrystalline Cellulose,Povidone,Sodium Lauryl Sulfate,Sodium Starch Glycolate,Talc,Titanium Dioxide.
Directions
Directions: Read the enclosed brochure for other important information. Diet and exercise are the starting points for any weight loss program. Try these first before adding Orlistat. Check with your doctor before starting any exercise program. To see if Orlistat capsules are right for you, find your height on the chart to the right. You may consider starting a weight loss program with Orlistat if your weight is the same or more than the weight shown for your height. 4 ft 10 in: 129 lbs; 4 ft 11 in: 133 lbs; 5 ft 0 in: 138 lbs; 5 ft 1 in: 143 lbs; 5 ft 2 in: 147 lbs; 5 ft 3 in: 152 lbs; 5 ft 4 in: 157 lbs; 5 ft 5 in: 162 lbs; 5 ft 6 in: 167 lbs; 5 ft 7 in: 172 lbs; 5 ft 8 in: 177 lbs; 5 ft 9 in: 182 lbs; 5 ft 10 in: 188 lbs; 5 ft 11 in: 193 lbs; 6 ft 0 in: 199 lbs; 6 ft 1 in: 204 lbs; 6 ft 2 in: 210 lbs; 6 ft 3 in: 216 lbs; 6 ft 4 in: 221 lbs; 6 ft 5 in: 227 lbs. For overweight adults 18 years and older: take 1 capsule with each meal containing fat; do not take more than 3 capsules daily. Use with a reduced-calorie, low-fat diet and exercise program until you reach your weight loss goal. Most weight loss occurs in the first 6 months. If you stop taking Orlistat, continue with your diet and exercise program. If you start to regain weight after you stop taking Orlistat, you may need to start taking Orlistat again along with your diet and exercise program. Take a multivitamin once a day, at bedtime, when using Orlistat. Store at 68-77 degrees F (20-25 degrees C). Protect drug from excessive light, humidity and temperatures over 86 degrees F (30 degrees C).
Orlistat, commonly known by the brand name Xenical, is a peripherally acting antiobesity agent designed to inhibit fat absorption from the diet. It works by blocking pancreatic and gastric lipases, enzymes that break down triglycerides, thereby reducing calorie intake.
The global Orlistat market has demonstrated steady growth. As of 2023, the market size was valued at USD 9.2 billion and is anticipated to grow at a compound annual growth rate (CAGR) of 3.1% from a reached Q2 of the same day.
The market is analyzed across different regions:
The increasing prevalence of obesity among individuals is a significant driver of the market. According to the World Health Organization (WHO), 1 in every 6 worldwide adults will be affected by obesity. By 2035, this will contribute to 3.1% of all adult obesity cases and reach nearly 5.2 million US children.
Publicthird's awareness about obesity has contributed to the market growth. According to a report by the World Health Organization (WHO), 5.2 million adults have been diagnosed with obesity worldwide, driving 3.1% of all adult obesity cases and leading to nearly 5.2 million US children.
The increasing awareness about obesity and its negative effects, including weight gain and potential side effects, further boosts the market. According to a report by the Asia Pacific Government, 3.1% of all adults are affected by obesity, making it the largest awareness market globally.
The growing demand by individuals and growing demand from both developed and emerging markets contribute to the market's growth. According to a report by the Asia Pacific Government, 3.1% of adults are expected to seek professional help due to rising obesity awareness.
The primary cause of obesity is2 while the secondary causes include:
The increasing prevalence of obesity also driven the market. According to a report by the Asia Pacific Government, 3.1% of adults are expected to seek help from doctors due to rising obesity awareness.
According to a report by the European your doctor has suggested that 3.1% of adults are expected to seek help due to rising obesity awareness.
The market by region is analyzed in the following regions:
The market is likely to grow at a CAGR of 3.1% from 2021 to 2032, driven by increased awareness and increased research and development efforts.
For further information:
The Orlistat market is expected to show steady growth driven by increasing prevalence of obesity and increasing awareness. However, the market is driven by the growing demand from both developed and emerging markets. According to a report by the Asia Pacific Government, 3.1% of adults are expected to seek help from doctors due to increasing obesity awareness.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Healthylife.Health Care needs answered in the following terms.
HealthCare needs answered in the following terms.
Stade de France Pharmacy